# EDGAR Filing Document

**Accession Number:** 0002079013
**File Stem:** 0000000000-25-009458
**Filing Date:** 2025-9
**Character Count:** 14886
**Document Hash:** 7bb5793622cfb960a7ee84e5ede50e14
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-009458.hdr.sgml**: 20260326

**ACCESSION NUMBER**: 0000000000-25-009458

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250902

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Hall Chadwick Acquisition Corp
- **CENTRAL INDEX KEY:** 0002079013
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-289333

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** HARNEYS FIDUCIARY (CAYMAN) LIMITED
- **STREET 2:** 103 SOUTH CHURCH STREET
- **CITY:** GRAND CAYMAN
- **PROVINCE COUNTRY:** E9
- **ZIP:** KY1-1002
- **BUSINESS PHONE:** 284-852-4333

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** HARNEYS FIDUCIARY (CAYMAN) LIMITED
- **STREET 2:** 103 SOUTH CHURCH STREET
- **CITY:** GRAND CAYMAN
- **PROVINCE COUNTRY:** E9
- **ZIP:** KY1-1002
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001829126-25-005870

## Text-Extract

```

                                                            September 2, 2025

Alex Bono
Chief Executive Officer
Hall Chadwick Acquisition Corp
1 North Bridge Road
#18-06 High Street Centre
Singapore, 179094

       Re: Hall Chadwick Acquisition Corp
           Registration Statement on Form S-1
           Filed August 6, 2025
           Amendment No. 1 to Registration Statement on Form S-1
           Filed August 25, 2025
           File No. 333-289333
Dear Alex Bono:

     We have reviewed your registration statement and amendment and have the
following
comments.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Amendment No. 1 to Registration Statement on Form S-1
Cover Page

1.     You state that each unit includes one right to receive one-tenth of one
Class
       A ordinary share. Please expand your disclosure to explain that no
fractional shares
       will be issued in connection with an exchange of the share rights, as
stated on page 20
       of your prospectus. Refer to Item 501(b)(2) of Regulation S-K.
Summary, page 1

2.     You state that your sponsor is an affiliate of Hall Chadwick, an
accounting and
       business advisory firm, and also state that Hall Chadwick is a
"promoter." Please
 September 2, 2025
Page 2

      clarify your defined terms to establish what entity you refer to
throughout your
      prospectus as "Hall Chadwick." In this regard, we note the overlapping
names of you,
      your sponsor, and your sponsor's affiliate. To the extent applicable,
please revise your
      disclosures in the Summary, and elsewhere in your prospectus as
appropriate, to
      provide appropriate disclosures regarding Hall Chadwick, such as expanded
      disclosures regarding its roles and responsibilities, any compensation
payable to it,
      and any actual or potential conflicts that may arise from your sponsor's
connection
      with Hall Chadwick. See, for example, Items 1602(b)(6), 1602(b)(7),
1603(a)(3), and
      1603(a)(4) of Regulation S-K.
Advisory Team Members, page 6

3.    We note your advisory team members, each of whom is affiliated with Hall
      Chadwick. Please expand your disclosure regarding your advisory team to
disclose the
      members' roles and, to the extent applicable, also expand your disclosure
on page 13
      to cover any compensation that may be payable to them or securities that
may be
      issued to them. Refer to Items 1602(b)(6) and 1603(a)(4) of Regulation
S-K.
Sponsor Information, page 12

4.    You state that your chairman, two of your directors, and two of your
officers, will
      own direct and indirect interests in your sponsor. Please revise to
identify these
      persons who have direct and indirect material interests in your sponsor,
and also
      disclose, as of the most recent practicable date, the nature and amount
of their
      interests, or advise. Refer to Item 1603(a)(7) of Regulation S-K.
5.    Please expand the disclosures regarding the transfer restrictions
applicable to the
      private placement units to refer to the individuals subject to such
restrictions. See Item
      1603(a)(9) of Regulation S-K. In this regard, we note that the letter
agreement filed as
      Exhibit 10.1 states that various "Insider" individuals have agreed to
these restrictions.
6.    We note your disclosures here and elsewhere in your prospectus that your
sponsor,
      directors, and officers have agreed to waive their redemption rights with
respect to
      their founder shares, private placement shares, and public shares in
connection with
      the completion of the initial business combination. However, the letter
agreement
      filed as Exhibit 10.1 indicates that the sponsor and insiders have agreed
to not redeem
      any Class A shares held by them. In this regard, we note that the founder
shares held
      by them are Class B ordinary shares. Please revise to reconcile, or
advise.
Corporate Information, page 17

7.    Please reconcile your disclosure here that your executive offices are
located at a P.O.
      Box associated with Harneys Fiduciary in the Cayman Islands with your
cover page
      disclosure listing your principal executive offices in Singapore.
The Offering, page 20

8.    We refer you to your disclosure at the bottom of page 20 and the top of
page 21. It
      does not appear that the disclosure of the number of units outstanding
after this
      offering, number of share rights to be sold as part of the units in a
private placement
      simultaneously with this offering, and number of share rights to be
outstanding after
 September 2, 2025
Page 3

       this offering are inclusive of the 180,000 private placement units to be
issued to the
       underwriters. Please revise, or advise.
Appointment and removal of directors. . .Voting Rights, page 24

9.     We refer to your statements regarding the need for 9,609,869 and
1,054,479 of the
       public shares to be voted in favor of an initial business combination in
connection
       with seeking approval of such transaction with an ordinary resolution.
Please explain
       to us your calculations. In this regard, we note your disclosures
elsewhere that you
       will have 25,424,639 shares after the offering, and that there will be
over 7.4 million
       founder shares, private placement shares and private placement shares
issued to the
       underwriter. Please also revise your disclosures as appropriate to
describe the terms of
       any voting agreement between you and the underwriter with respect to its
private
       placement shares.
Summary Risk Factors, page 43

10.    Please revise the fifth bullet point here to explain the low number of
public shares
       sold in this offering that you would need to approve the initial
business combination,
       as you discuss elsewhere in your prospectus, and also revise your fourth
bullet to
       explain the terms of any voting agreement between you and the
underwriters with
       respect to their private placement units.
We may engage our underwriters. . ., page 49

11.    Please expand this risk factor to also discuss the conflicts of interest
risks arising from
       the underwriters' ownership of the private placement units.
We may not be able to complete an initial business combination because such
initial business
combination. . ., page 71

12.    Please revise this risk factor to clarify whether your sponsor is
controlled by, has any
       members who are, or has substantial ties with, a non-U.S. person.
Dilution, page 100

13.    We note your dilution disclosures beginning on page 100 appear to have
multiple
       errors. For example purposes only, and not intended to be an exhaustive
list, we noted
       the following:
           It does not appear that the amounts reflected as your pro forma net
tangible book
           value per share after the offering without any redemptions or under
any of the
           redemption scenarios are supported by the numerator and denominator
detail
           calculations disclosed on page 101. For example, under a no
redemption scenario,
           your disclosure on page 100 indicates that the pro forma net
tangible book value
           per share after the offering is $8.89; however, based on your
numerator and
           denominator disclosure on page 101, it appears that the pro forma
net tangible
           book value per share would be $6.92.
           Under your 50% redemption scenario, it is unclear how the Company
determined
           that 11,385,000 shares should be redeemed under the full
over-allotment scenario.
           Under the 100% maximum redemption scenario, it is unclear how you
determined
 September 2, 2025
Page 4

          that 17,500,000 and 20,400,000 shares are to be redeemed under the No
Over-
          Allotment and Full Over-Allotment scenarios, respectively.
       As noted above, these bullets are not intended to be an exhaustive list.
Please revise
       your dilution disclosures for accuracy, or advise.
14.    We note your statement on page 100 that the below calculations assume
"...7,500
       Class A ordinary shares (maintained at 7,500 if the over-allotment
option is exercised)
       upon the conversion of the Share Rights and 30,500 Class A ordinary
shares (or up to
       33,200 if the underwriters    over-allotment option is exercised) upon
the conversion of
       the private placement units share rights to the underwriter." Please
address the
       following:
           Please clarify for us how you derived the share amounts in this
statement, or
           revise for accuracy.
           We are unclear how the below calculations include the impact of any
share rights,
           please advise or revise.
           If applicable, please expand your narrative disclosure to describe
each material
           potential source of future dilution, include shares that may be
issued in connection
           with the conversion of the share rights. Reference is made to Item
1602(c) of
           Regulation S-K.
15.    Please expand your disclosure outside the table to highlight that you
may need to issue
       additional securities because you intend to target businesses with
enterprise values
       greater than the net proceeds of this offering and the sale of the
private placement
       units, as stated on page 12 of your prospectus.
Capitalization, page 102

16.    Please revise to populate the remainder of the as adjusted column, or
advise.
17.    Please revise your line item description for Class A ordinary shares and
Class B
       ordinary shares to reflect the correct amount of shares issued and
outstanding, as
       adjusted, or tell us how your line item descriptions are accurate.
Management, page 146

18.    Please revise the biographies of your officers and director nominees to
reflect each
       person's business experience and roles over each of the past five years.
Refer to Item
       401(e) of Regulation S-K.
Financial Statements, page F-1

19.    We note your disclosure on page F-16 that 1,018,654 Class B ordinary
shares are
       subject to forfeiture if the underwriters do not exercise their
over-allotment option in
       full. Please revise your balance sheet and statement of changes in
shareholder's equity
       to include a notation that the amount of Class B ordinary shares issued
and
       outstanding includes 1,018,654 Class B ordinary shares subject to
forfeiture if the
       underwriters do not exercise their over-allotment option in full. This
comment also
       applies to your Summary Financial Data on page 43.
 September 2, 2025
Page 5
Statement of Profit and Loss, page F-4

20.    We refer you to your disclosure on page F-12 that the weighted average
shares were
       reduced for the effect of an aggregate of 1,018,654 ordinary shares that
are subject to
       forfeiture if the over-allotment option is not exercised by the
underwriters. It does not
       appear that the disclosure on page F-12 is consistent with the weighted
average shares
       amount on your statement of profit or loss. Please revise for
consistency or advise.
Notes to Financial Statements
Note 4. Private Placement, page F-13

21.    We note your disclosure on page F-13 that the sponsor, officers and
directors have
       waived their redemption rights in certain scenarios. Please revise your
filing as
       appropriate, including to the extent applicable, the private placement
units purchase
       agreement filed as Exhibit 10.4(b), to clarify for us if your
underwriters have also
       waived their redemption rights for their 180,000 private placement
shares.
Exhibits

22.    We refer to your Cayman Islands legal opinion filed as Exhibit 5.2.
Please file an
       amended legal opinion removing any inappropriate assumptions. It is not
appropriate
       for counsel to include in its opinion assumptions that assume any of the
material facts
       underlying the opinion. In this regard, as one example, we note that
paragraph 7
       assumes such material facts. Please also attach a copy of the director's
certificate
       referenced in your opinion. Refer to Section II.B.3.a of Staff Legal
Bulletin No. 19.

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

        Please contact Ameen Hamady at 202-551-3891 or Jennifer Monick at
202-551-
3295 if you have questions regarding comments on the financial statements and
related
matters. Please contact Isabel Rivera at 202-551-3518 or Dorrie Yale at
202-551-8776 with
any other questions.

                                                             Sincerely,

                                                             Division of
Corporation Finance
                                                             Office of Real
Estate & Construction
cc:   Andy Tucker

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._